Psychopharmacology of anxiety

Psychiatry

Volumn 6, Issue 4, 2007, Pages 143-148

  Nash, Jon ^a,b   Nutt, David ^a,b  

^a Jon Nash MRCP MRCPsych is a Specialist Registrar in Learning Disability Psychiatry in Weston super M   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

anticonvulsant; antidepressant; anxiety; benzodiazepine; GABA; MAOI; mirtazapine; noradrenaline; pharmacotherapy; serotonin; SNRI; SSRI; TCA

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PAROXETINE; PHENELZINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ADD ON THERAPY; ADJUVANT THERAPY; AGGRESSION; ANXIETY; ANXIETY DISORDER; APPETITE; ASTHENIA; BEHAVIOR THERAPY; CLINICAL ASSESSMENT; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONSTIPATION; DEPRESSION; DROWSINESS; DRUG CHOICE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; GENERALIZED ANXIETY DISORDER; GOOD CLINICAL PRACTICE; HEADACHE; HUMAN; HYPERHIDROSIS; HYPERTENSION; HYPONATREMIA; INSOMNIA; LOW DRUG DOSE; MENTAL DISEASE; MENTAL HEALTH CARE; MONOTHERAPY; NAUSEA; NERVOUSNESS; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PANIC; PATIENT MONITORING; PHOBIA; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SELF MONITORING; SEXUAL DYSFUNCTION; SIDE EFFECT; SOCIAL PHOBIA; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SYMPTOM; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WITHDRAWAL SYNDROME;

EID: 34047150008     PISSN: 14761793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mppsy.2007.02.001     Document Type: Review

References (23)

1. Nutt D.J. The unhappy saga of happy pills. J Psychopharmacol 17 (2003) 251
2. Baldwin D.S., Anderson I.M., Nutt D.J., et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19 (2005) 567-596
3. National Institute for Clinical Excellence. Anxiety. Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guideline 23 (2004), National Collaborating Centre for Mental Health, London
4. Bandelow B., Zohar J., Hollander E., Kasper S., and Moller H.J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3 (2002) 171-199
5. Wilk J.E., West J.C., Narrow W.E., et al. Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis?. Compr Psychiatry 47 (2006) 258-264
6. Ballenger J.C., Davidson J.R., Lecrubier Y., and Nutt D.J. A proposed algorithm for improved recognition and treatment of the depression/anxiety spectrum in primary care. Prim Care Companion J Clin Psychiatry 3 (2001) 44-52
7. American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder (1998), American Psychiatric Association, Washington, DC
8. Nutt D.J. Death by tricyclic: the real antidepressant scandal?. J Psychopharmacol 19 (2005) 123-124
9. Haddad P. The SSRI discontinuation syndrome. J Psychopharmacol 12 (1998) 305-313
10. Stahl S.M., Grady M.M., Moret C., and Briley M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 10 (2005) 732-747
11. Chessick C.A., Allen M.H., Thase M., et al. Azapirones for generalized anxiety disorder. Cochrane Database Syst Rev 19 (2006) CD006115
12. Barnett S.D., Kramer M.L., Casat C.D., Connor K.M., and Davidson J.R. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 16 (2002) 365-368
13. Nutt D.J. Overview of diagnosis and drug treatments of anxiety disorders. CNS Spectrums 10 (2005) 49-56
14. Schweizer E., and Rickels K. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatr Scand 393 (1998) S95-S101
15. Royal College of Psychiatrists. Benzodiazepines: risks, benefits or dependence. A re-evaluation. Council Report CR59 (1997)
16. Van Ameringen M., Mancini C., Pipe B., and Bennett M. Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs 64 (2004) 2199-2220
17. Montgomery S.A. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother 7 (2006) 2139-2154
18. Barlow D.H., Gorman J.M., Shear M.K., and Woods S.W. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 283 (2000) 2529-2536
19. Roy-Byrne P.P., Craske M.G., Stein M.B., et al. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry 62 (2005) 290-298
20. Furukawa T.A., Watanabe N., and Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br J Psychiatry 188 (2006) 305-312
21. Otto M.W., Basden S.L., Leyro T.M., McHugh R.K., and Hofmann S.G. Clinical perspectives on the combination of d-cycloserine and cognitive-behavioral therapy for the treatment of anxiety disorders. CNS Spectr 12 (2007) 51-61
22. Witkin J.M., Tzavara E.T., and Nomikos G.G. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 16 (2005) 315-331
23. Strohle A. New pharmacological treatment approaches for anxiety disorders. In: Handbook of Experimental Pharmacology. Anxiety and Anxiolytic Drugs 169 (2005) 503-526